Vor Biopharma News and Activities

Vor Biopharma is a company listed under the stock ticker VOR (US).

Acquisition, funding and merger involving Vor Biopharma.

• Vor Biopharma and Incyte have announced they will merge  (posted on June 30 2025)..

View the org chart displaying its 13 main executives

Most searched biographies at Vor Biopharma

• Jean-Paul Kress, Chief Executive Officer
• Daniella Beckmann, Director
• Erez Kalir, Director

Popular executive movements at Vor Biopharma

• Tania Philipp, Chief People Officer, has left the company  (posted on April 22 2026).
• Qing Zuraw, Chief Development Officer, has left the company  (posted on January 5 2026).
• Andrew Levin has joined the company as Director  (posted on December 25 2025).

Click here to view some more movements at Vor Biopharma

Create your alert
to follow the executive moves at Vor Biopharma.

Vor Biopharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Vor Biopharma

• Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design | Vor Bio
• Vor Bio to Participate in the Stifel 2024 Healthcare Conference | Vor Bio
• Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update | Vor Bio
• Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer | Vor Bio
• New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies | Vor Bio
• Vor Bio to Participate in Upcoming Investor Conferences | Vor Bio
• Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update | Vor Bio
• Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Vor Bio
• Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Vor Bio
• Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Vor Bio
• View more press releases Close

Social media about Vor Biopharma

• Vor Biopharma on Wikipedia, Google News & Yahoo Finance
• Vor Biopharma on LinkedIn, X (Twitter) & YouTube